← Patent-cliff monitor small molecule QINLOCK RIPRETINIB
Loss of exclusivity October 2042 latest FDA-listed patent expiry
Drug detail Brand name QINLOCK Active ingredient RIPRETINIB Strength 50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2020 Marketing status RX
Listed patents Patent Expires Type 11779572 October 2042 use U-3714 11969414 February 2041 use U-3897 12213967 December 2040 product 11896585 December 2040 product 12318374 December 2040 product 11576903 December 2040 product 11903933 December 2040 product 12226406 December 2040 product 11844788 December 2040 product 11850240 December 2040 product 12213968 December 2040 product 11850241 December 2040 product 11395818 December 2040 product 11612591 December 2040 product 11185535 December 2040 product 11793795 December 2040 product 12064422 December 2040 use U-3219 11969415 December 2040 use U-3219 11801237 December 2040 product 11911370 December 2040 product 12708617 December 2040 use U-3219 12023328 December 2040 use U-3957 11918564 December 2040 product 12059411 August 2040 use U-3971 12295944 August 2040 use U-4183 11433056 August 2040 use U-3423 12023327 August 2040 use U-3958 12023326 August 2040 use U-3959 12023325 August 2040 use U-3960 11529336 August 2040 use U-3382 11534432 August 2040 use U-3442 12318373 August 2040 use U-4191 11813251 August 2040 use U-3750 11344536 August 2040 use U-3381 11266635 August 2040 use U-3330 11576904 August 2040 use U-3537 10966966 August 2040 use U-3153 11426390 August 2040 use U-3416 12059410 August 2040 use U-3153 8461179 May 2034 substance, product RE48731 June 2032 use U-3219 8188113 July 2030 substance, product
Regulatory exclusivity Code Expires ODE-298 May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.